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ABSTRACT 
Despite the chronic debate in the etiology of Crohn’s disease (CD), a debilitating 
inflammatory bowel disease (IBD) closely related to ulcerative colitis (UC), an emerging interest 
in a possible mycobacterial role has been marked. Granuloma and pathologic manifestations in 
CD resemble aspects found in tuberculosis, leprosy and paratuberculosis. The latter, a chronic 
enteritis in cattle, goat, sheep and primates, which is similar to human enteritis, also known as 
CD, is caused by a fastidious, slow growing Mycobacterium avium subspecies paratuberculosis 
(MAP).  Due to the similarities between CD and paratuberculosis, a mycobacterial cause in CD 
has been proposed.  Recent discovery of a possible association between NOD2/CARD15 
mutations and risk of CD added support to microorganism-host interactions. In this study, a 
possible mycobacterial role in CD etiology has been evaluated by investigating the presence of 
MAP DNA, the state of the cellular immune response and microarray gene expression profiling 
in peripheral blood and surgical tissue from CD, UC and healthy control subjects. Nested PCR 
detected MAP DNA in tissue from 10/12(83%) CD patients compared to 1/6(17%) non-IBD 
subjects. Fluorescence in situ hybridization (FISH) with the aid of Confocal Scanning Laser 
Microscopy (CSLM) detected MAP DNA in 8/12(67%) CD subjects compared to 0/6(0%) in 
non-IBD subjects.  The detection of MAP DNA by either technique in tissue from CD subjects is 
significant compared to non-IBD subjects (P < 0.05). MAP DNA was also detected in both 
inflamed and non-inflamed tissue from patients with CD suggesting MAP infiltration in human 
tissue. Correlation of possible MAP presence and the function of polymorphonuclear leukocytes 
(PMN) and peripheral blood mononuclear cells (PBMC) in 19 CD patients and 12 controls have 
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been evaluated. PMN phagocytosis of viable FITC-MAP was suppressed in 13/19(68%) CD 
patients compared to 0/12(0%) in healthy controls (P<0.05).  PBMC phagocytosis of viable 
FITC-MAP was suppressed in 5/19(26%) of CD patients compared to 0/12(0%) of healthy 
controls (P<0.05). The proliferative response of PBMC with T-cell majority from CD and 
controls subjects was evaluated against PHA, Candida albicans, PWM and MAP PPD.  
Dysfunctional proliferative response against PHA was found in 8/19(42%) CD patients 
compared to 1/12(8.3%) in controls suggesting possible T-cell anergy.  PBMC from 11 CD 
subjects reacted normally to PHA, 7/11(64%) reacted strongly to MAP PPD suggesting previous 
exposure to mycobacteria, and 3/11(27%) did not react with MAP PPD suggesting lack of pre-
exposure to mycobacteria.  From the seven mycobacterial pre-exposed samples, 6/7(86%) 
showed a normal ability to recall antigens by activated macrophages when exposed to C. 
albicans, and all 7 samples had a normal PWM response.  Finally, microarray-chip technology 
was employed to identify the expression profile of genes that have a role in the immune response 
of CD patients.  RNA was isolated from fresh buffy coats from 8 healthy controls, 2 CD, and 1 
UC patients.  Chips with an estimated of 30,000 human genes were hybridized to cDNA from 
these samples.  We found that 17% of the total number of genes was differentially expressed.  
Over 200 genes were involved in the immune response, 7 genes where common to both forms of 
IBD (UC and CD), and 8 genes were found to be either downregulated in CD and upregulated in 
UC or viceversa.  The IFNGR1 gene, which encodes the ligand-binding chain of the IFN-gamma 
receptor, was found to be downregulated in 2/2(100%) of CD patients, but not in UC patients.  It 
is known that defects in IFNGR1 are a cause of atypical mycobacterial infection and bcg 
infection.  Patients suffering from this deficiency have an immunologic defect predisposing them 
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to infection with mycobacteria.  This correlates with the proposed theory as MAP being the 
causative agent of CD.  Furthermore, the results indicate a host susceptibility requirement for the 
establishment of mycobacterial infection in CD patients.  Further characterization of IFNGR1 
using real-time PCR is underway. Collectively, detection of MAP DNA in the majority of CD 
tissue and the alteration in PMN and PBMC to respond efficiently to MAP may be related to the 
fact that mycobacterial pathogens infect phagocytic cells of susceptible hosts and consequently 
the immune response is dysregulated. Furthermore, the fact that a gene linked to mycobacterial 
susceptibility was found to be downregulated in CD patients only, strengthens the mycobacterial 
etiology of CD.  In general, the data suggest a possible role for a bacterial pathogen in CD 
pathogenesis. 
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CHAPTER ONE: INTRODUCTION 
Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) of controversial 
etiology with more than 500,000 people affected in the United States alone (27, 14). Although 
CD was initially described as a segmental disease of the small intestine, it has more recently 
been found to be associated with the mouth, larynx, esophagus, stomach, colon, skin, muscle, 
synovial tissue, and bone involvement (16, 17). The similarity in pathological manifestations and 
other aspects present in CD with those in animals diagnosed with paratuberculosis (also known 
as Johne’s disease; JD) was first described by Dalziel (17) and later on by Chiodini (12).  JD is a 
chronic inflammatory disease of ruminants caused by Mycobacterium avium subspecies 
paratuberculosis (MAP), a slow grower, fastidious and intracellular pathogen (74). Chiodini et 
al. isolated cell-wall deficient organisms, also known as spheroplast, from tissue of patients with 
CD following long term incubation culture (11). The spheroplast cultures then reverted to acid-
fast mycobacterium-like organism after a single in vitro passage (10, 11). They were confirmed 
as MAP culture using IS900 probe (55). This was followed by several studies, which resulted in 
mixed results (18, 33, 52, 57, 59, 71, 76, 82, 86).  Although, the culture methodology remains the 
most sensitive and convincing approach for confirming or excluding a mycobacterial role in CD 
etiology, this approach faces many obstacles related to the fastidious characteristics and lack of 
cell wall of the MAP bacterium in human CD tissue. There is a need for additional 
methodologies where MAP may be identified directly in tissue specimens. As reported in the 
literature, regions in the 1.451 kb IS900 sequence remain to be unique to MAP (33).  Ultimately, 
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these IS900-derived nucleotide sequences may be used as markers for verification of MAP 
involvement in tissue (7, 40), and in milk from patients with CD (62).  
Patients with CD tend to have abnormalities in the immune system, but it is not clear 
whether these abnormalities are cause or result of the disease. There are a variety of cellular 
processes and pro-inflammatory mediators that influence the pathogenesis of the disease.  It is 
believed that there is a continuous immune response in the gut in response to an environmental 
stimuli..  CD has been classified into two distinct disease subtypes: a perforating form and a non-
perforating form (34, 40, 57).  This dual clinical presentation also renders CD analogous to two 
other mycobacterial diseases, leprosy and tuberculosis, which both manifest in two distinct 
clinical forms: a contained form and an aggressive form. (35, 80, 85).  As with tuberculosis and 
leprosy, the various manifestations of the infections are attributable to the interactions with, and 
the plasticity of, the immune response (80).  Many of the systemic findings are attributable to the 
pro-inflammatory cytokines that are released (IL-1, TNF-alpha, etc).  MAP may be resistant to 
killing by macrophages and/or PMN, and M. avium has been shown to be resistant to killing by 
dendritic macrophages (58). Given the similarities between tuberculosis and CD, T-cell anergy 
as a result of persistent antigen stimulation may be relevant to granuloma formation and 
inflammation in CD disease. Further evidence that supported the role of MAP in CD etiology 
was reported including the detection of anti-MAP IgG antibodies in sera from significant CD 
patients compared to controls (23, 61, 77). 
In 2001, the first susceptibility gene for CD, NOD2 (nucleotide-binding oligomerization 
domain), was identified (43, 68).  NOD2 is expressed in the cytoplasm of monocytes, and it is 
comprised of N-terminus caspase-activation recruitment domains (CARD), a central nucleotide-
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binding domain, and a C-terminus leucine-rich repeat (LRR) domain.  The LRR domain is 
required for NOD2 signaling in response to muramyl dipeptide (MDP), the minimally active 
component of bacterial cell wall peptidoglycan.  Mutations in NOD2 gene have been shown to 
be associated with CD, suggesting a role for intracellular pathogen-host interactions in the 
etiology of CD.  Genetic defects, which result in modification or inactive cytokines or signaling 
molecules, may also disrupt immune function (20, 67).  A point mutation in the coding region of 
the gene for interferon-gamma receptor 1 results in a new stop codon and in the production of a 
truncated protein that results in failure of interferon-gamma to stimulate proper antigen 
processing and presentation and increased susceptibility to mycobacterial infection (46).   
Rationale for the study 
The mystery of IBD with regard to etiology and pathogenesis led to controversial 
approaches in diagnosis and treatment of these diseases. Ultimately, IBD sufferers are subjective 
to the knowledge and expertise of their attending physicians. Consequently, the treatment of 
patients with IBD may vary from one clinic to another and from geographic region to the next. 
There is an immediate need for focused research that may unravel the mystery of IBD, especially 
CD. Unraveling the etiology of CD will go a long way toward targeted treatment and ultimately 
curing the disease rather than containing it.  The purpose of this work is to comprehensively 
study the mycobacterial etiology, as has been proposed in the literature, of CD by investigating 
possible resemblance in immunological events that occur in tuberculosis and CD patients. 
Subjects enrolled in this study were approved by IRB (institutional review board) regulation at 
the University of Central Florida and University of Florida. Accordingly, coded peripheral blood 
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and tissue samples were collected, processed and analyzed.  Specifically, clinical samples from 
patients with CD, UC, non-IBD and healthy controls were used to investigate the presence of 
MAP DNA, immunogenicity of immune cells and to study gene expression profiling.  
Ultimately, better understanding of mycobacterial association with CD may be determined. The 
impact of this research will be tremendous on millions of IBD sufferers in terms of diagnosis and 
treatment. 
 
4 
  
CHAPTER TWO: EVALUATION OF SURGICAL TISSUE FROM 
PATIENTS WITH CROHN’S DISEASE FOR THE PRESENCE OF 
MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS DNA 
BY IN-SITU HYBRIDIZATION AND NESTED PCR 
Introduction 
In situ detection of nucleic acid sequences provides a direct visualization of the spatial 
location of specific sequences that is important for diagnosis of bacterial and viral infections 
(63).  Confocal scanning laser microscopy (CSLM) is a technique where the specimen is 
illuminated by a focused beam of light. An image is recorded by scanning the beam of light over 
the specimen, and the reflected or fluorescent light from the specimen is focused onto a small 
detector aperture. This combination of point illumination and point detection results in a unique 
"optical sectioning" capability. This optical sectioning makes it possible to record images of thin 
layers within the specimen without cutting it into slices. By collecting a "stack" of such images 
from different depths, it is possible to display and quantify the three-dimensional structure of a 
specimen (3).  In this chapter, we have employed both fluorescence in situ hybridization using a 
specific MAP DNA probe and CLSM and two rounds of nested PCR in an attempt to investigate 
the presence or absence of MAP DNA in surgical tissue specimens from patients with CD, 
ulcerative colitis (UC) or non-IBD. 
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Methods and Materials 
Tissue Collection 
A total of 31 surgical resectioned full-thickness tissue specimens including 23 tissues 
from 12 CD subjects (consisting of 12 inflamed and 11 non-inflamed tissue), 2 inflamed tissue 
from 2 patients with UC and 6 cancerous tissue samples from 6 patients with colon cancer, were 
included in this study.  Coded tissue specimens were obtained at the time of surgery from 
consented participating subjects following Institutional  Review Board (IRB) Regulation.  The 
diagnosis CD or UC was established following standard clinical, endoscopic, histologic, and 
radiographic criteria (72). Disease activity was determined by use of the Harvey-Bradshaw index 
(37) and/or the clinical impression of the treating physician. The tissue specimens were kindly 
provided either by Dr. I. Shafran (Florida Hospital. Orlando, Florida) or by Dr. J. Valentine 
(University of Florida and Gainesville VAMC, Gainesville, FL). Samples representing inflamed 
and non-inflamed areas of the bowel from CD patients were sought. Colonic specimens from UC 
and other non-IBD patients that are undergoing colectomy or partial colectomy were also sought 
and used as controls. The tissue samples were examined macroscopically upon arrival, removed 
from the transport tube, flash frozen and stored in liquid nitrogen. Table 1 summarizes the 
demographic data related to subjects including disease history, use of immunosuppressive and 
the type of tissue samples used in the study. 
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Tissue Sectioning and Processing 
Tissue specimens were removed from liquid nitrogen, placed in the cryostat, left for 30 
min to equilibrate at –20 0C, placed onto cryostat tissue holders and embedded in mounting 
medium (OCT embedding medium, RA LAMB, NC). A total of 20 serial 20 um sections from 
each tissue specimen were cut, placed on 20 microscope slides, and allowed to air dry.  All slides 
containing tissue sections were fixed in 4% PFA (Sigma, MO) for 30 minutes at room 
temperature.  Under the same conditions, slides were then washed 3 times in PBS (pH 6.8).  
Tissue sections were permeabilized with 100uL (20ug/mL) of Proteinase K (Sigma, MO) and 1% 
of SDS for 30 min at 55oC.  Proteinase K was then inactivated with 200 uL of 0.2% glycine 
(Fisher Scientific, CA) for 3 min, and slides were then washed 3 times in PBS (pH 6.8). Tissue 
sections were dehydrated in 1 minute washes of 70%, 90%, and 100% ethanol.  Sections were 
then washed for 1min with 100% xylene (Fisher Scientific, CA) to remove excess lipids.  Tissue 
sections were re-hydrated with 1 m washes of 100%, 90%, and 70% ethanol and incubated in 
PBS (pH 6.8) at room temperature for 1 hour.  Finally, sections were incubated in 25 mL of pre-
hybridization solution (2X SSC, 20% dextran sulfate, and 50% formamide) for 5 min at 50oC 
immediately before hybridization. MAP cultured in our laboratory from CD tissue was used as a 
positive control to optimize the protocol conditions.  MAP was grown in MGIT media as 
described previously (76).  Growth was observed as non-homogenous turbidity in approximately 
8 weeks.  A volume of 0.05 mL was aseptically removed from the culture to a sterile 1.5 mL 
microcentrifuge tube and centrifuged at 10,000 rpm for 10 minutes at 4 oC.  The cell pellet was 
washed 3 times in PBS (pH 6.8) and then resuspended in 0.10 mL PBS, with 20 uL aliquoted to 
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each slide.  Several slides containing thin smear were prepared and then allowed to air dry in a 
Biosafety class II cabinet for 1 hour.  Slides were then heat fixed at 70 oC for 1 hour. 
Quality controls 
The FISH protocol was optimized earlier in the study by testing sections from normal 
tissue of colon cancer patients that were spiked with MAP ATCC strain 43015 and tissue 
sections  without the spiking with MAP.  The specificity of the IS900-labeled probe was tested 
using slides containing no bacterial smear, Escherichia coli, Mycobacterium smegmatis, 
Mycobacterium avium subspecies avium, Staphylococcus aureus and MAP. 
Probe Preparation and hybridization 
A 20-mer MAP specific oligonucleotide probe (5’-CTTCGGGGCCGTCGCTTAGG-3’) 
derived from the IS900 sequence was labeled at the 5’-end with fluorescein (Invitrogen, CA).  
Aliquots of 1ug/uL were stored at –20oC.  One hundred nanograms of fresh probe were mixed 
with 20 uL of hybridization solution (1% Triton X-100, 2X SSC, denatured sperm DNA (500 
ug/mL), 10% dextran sulfate, and 50% deionized formamide), boiled for 10 min and placed on 
ice for 10 more minutes.  The hybridization mixture was added to the tissue sections and placed 
inside a hybridization chamber (Corning inc., MA) overnight at 37oC.  After 24 h, tissue samples 
were removed from the chamber and extensively washed.  The first wash was with 2X SSC for 
15 min at room temperature, followed with another wash with 1X SSC under the same 
conditions.  The last 2 washes were done with 0.3X SSC, one for 15 min at 40 oC, and the other 
one for 15 min at room temperature.  Slides were then incubated in 40 mL of counterstain 
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solution containing 40 ng of propidium iodide (Sigma, MO) for 15 min at room temperature in 
the dark.  Slides were then washed three times with sterile water each time for 5 min at room 
temperature, and air-dried in the dark.  Slides were then mounted with anti-fade solution 
(Molecular Probes, OR) before storage to preserve the fluorescence. 
Confocal Scanning Laser Microscopy Analysis 
A Carl Zeiss LSM 510 system was used in this study (Carl Zeiss Inc., NY). Slides were 
examined to localize the targets on the slide by using transmitted-light.  Once the target was 
found, two simultaneous confocal channels were used for reflection and fluorescence.  The 
detector on the microscope was set to include light from the negative control, and was kept 
constant for all test samples. All variables, such as photometric gain, photomultipler setting, 
pixel size, objective size, and number of scans were recorded for each scan and were used 
comparatively for sample slides.  Using the Zeiss image analysis software, a treshold was applied 
to eliminate pixels with no fluorescence (black) and residual noise from the detector. Images 
with relevant data were saved for documentation. 
Statistical analysis 
Groups were compared in using 2x2 contingency tables and Fishers Exact test.  
Significant data had a P value < 0.05. 
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Genomic DNA Extraction and Nested PCR Analysis 
Approximately five hundred mg of fresh tissue was diced into fine pieces using sterile 
disposable scalpels. The tissue sample was re-suspended in 4.0 ml of lysis buffer (2mM EDTA, 
400 mM NaCl, 10 mM TrisHCl pH8, 100 ug/ml Proteinase K, and 0.6% SDS) and homogenized 
by an Omni Tip disposable generator probe (Fisher Scientific Pittsburgh, PA) for 1 min at 30,000 
rpm. The tissue was then incubated with shaking (200rpm) at 37°C for 3 hrs, transferred to 
disposable FastPrep® lysing matrix B blue cap tube (Qbiogene, Carlsbad, CA), and ribolysed at 
6.5m/s-2 for 45secs by using a FastPrep® ribolyser (Qbiogene, Carlsbad, CA). The lysates were 
placed on ice immediately for 15min.  The DNA was then isolated by 
phenol/chloroform/isoamyl alcohol and ethanol precipitation. DNA pellet was dissolved in 250 
µl TE buffer. The MAP specific IS900 DNA element was evaluated in triplicate using a nested 
primer PCR technique.  Briefly, oligonucleotide primers P90 (5'-GTT-CGG-GGC-CGT-CGC-
TTA-GG-3') and P91 (5'-GAG-GTC-GAT-CGC-CCA-CGT-GA-3') were selected to amplify a 
unique 398 bp fragment of 5' region of IS900. To reliably detect MAP, AV1(5'-ATG-TGG-TTG-
CTG TGT-TGG-ATG-G-3') and AV2(5'-CCG-CCG-CAA-TCA-ACT-CCA-G-3')  were used for 
the nested PCR in the second  round  using the amplified fragment as a template to amplify a 298 
bp internal sequence. The PCR reaction mixture of 50 µL consisted of 1×PCR buffer, 5mM 
MgCl
2
, 0.2mM dNTP, 6% DMSO or 0.5M Betaine, 2µM primers, and 2.5u Platinum Taq 
polymerase (Invitrogen Carlsbad CA) and 10µl of DNA template.  Five µl of DNA template was 
used in first around PCR reaction in 50µl. 1µl of PCR product from first round was used in 
second round PCR in 50µl. The PCR cycling conditions were as follows: 95°C for 5 min, 
10 
40cycles of 95°C for 1min, 58°C for 1min, 72°C for 3 min; and a final extension of 5 min at 
72°C.  The amplification product size was determined on an agarose gel. Some of the nested 
PCR products were gel purified and sequenced by the University of Florida DNA Sequencing 
Core facility confirming that the product was identical to the MAP IS900 sequence. 
Results 
A total of 20 patients who underwent for surgery for resection of bowel tissue were 
enrolled for this study between July 2002 and January 2004.  Twelve patients were diagnosed 
with CD, 2 with UC and 6 with colon cancer (non-IBD). The median age was 41 yr for CD 
patients and 52 yr for non-CD patients equally distributed as males and females. The data in 
Table 1 shows that 11 out of 12 (92%) CD patients were on immunosuppressive medications, 
Neither of the 2 patients with UC nor the 6 non-IBD controls were on immunosuppressive 
medications. 
Specificity of the IS900-Based FISH 
Using slides containing cultures representing MAP, M. smegmatis, M. avium subspecies 
avium, Staphylococcus aureus and E. coli were used to test the specificity of the FITC-labeled 
IS900-derived DNA probe. As shown in Fig. 1, the presence of MAP was detected as a yellow 
color indicating the colocalization of the FITC-green fluorescence labeled-IS900 probe 
hybridized with corresponding MAP DNA present in the bacterial samples (E). Slides containing 
E. coli (A), Staphylococcus aureus (B) and M. smegmatis (C) and M. avium subspecies avium 
(D) cultures were negative against the FITC-labeled IS900 probe. Hybridization signals with 
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MAP DNA were detected mostly in clumps distribution, a typical characteristic of mycobacterial 
morphology following microscopic staining. Slides without any bacterial smear were blank (data 
not shown).  All the variables mentioned above including various dilutions of bacterial cells and 
probes were repeated several times with duplicate slides in every attempt. The results remained 
consistent at all times. After several attempts for adjustment of variables, parameters were 
identified and then employed during this study. MAP was absent in slides containing sections 
from normal tissue of a colon cancer patient when analyzed using the optimized protocol 
described earlier (Fig. 2A). However, MAP in clumps was clearly visualized in slides with tissue 
sections spiked with MAP culture (Fig. 2B). 
Detection of MAP DNA in Tissue by FISH and CSLM 
Slides containing CD and non-CD tissue sections were used, and the presence of MAP 
was detected as a yellow color indicating the specific hybridization of the green fluorescent MAP 
probe with the MAP DNA present in the red stained human tissue samples.  For the isotypic 
control slides, PBS was used instead of MAP probe to establish the threshold to eliminate 
residual noise during image analysis. In 12 CD patients tissue, MAP DNA was detected in 7/12 
(58%) of inflamed, 4/11 (36%) of non-inflamed and in 8/12 (67%) of either tissue type (Table 2). 
Fig. 3 illustrates representative CLSM images of tissue sections from CD patients following 
hybridization with the IS900 probe; MAP DNA was detected only in inflamed tissue (A:I), only 
in non-inflamed tissue (B:N) and in both inflamed and non-inflamed tissue (C:I and C:N). MAP 
infiltration was observed in three CD patients since both tissue types contained MAP DNA. On 
the contrary, MAP DNA was absent in both Tissue types in two CD patients.  As shown in Fig. 
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4, MAP DNA was not detected in tissue sections from all six non-IBD patients (A to F). 
Detection of MAP DNA by FISH in 67% of CD tissue compared to zero in non-CD tissue is 
significant (P < 0.005). 
Detection of MAP DNA in Tissue by Nested PCR 
In order for low level of MAP DNA to be specifically detected, the second round of the 
nested PCR technology was employed in this study which amplifies an internal 298 bp fragment 
from a template of 398 bp fragment amplified in the first round of the PCR. An intense bright 
band has been observed in all positive results. The amplified fragment was confirmed to be 
IS900 by nucleotide sequencing. . In this study, a total of 31 DNA extracts isolated directly from 
homogenized 31 tissue samples were analyzed. As shown in Table 2, MAP DNA was detected in 
tissue from 10/12 (83%) of CD subjects, 2/2 (100%) inflamed tissue from 2 UC patients 
compared to 1/6 (17%) of non-IBD subjects (P<0.005). Interestingly, MAP DNA in CD tissue 
was detected in 7 inflamed samples (Fig. 5A, lanes 4, 8,10, 14 and Fig 5B, lanes 4, 6, 8) and in 6 
of non-inflamed samples (Fig. 5A, lanes 3, 5, 11, 13, 15, and Fig. 5B, lane 3).  MAP DNA in 
non-IBD tissue was detected in two tissue samples (Fig. 5B lanes 9 and 10). 
Discussion 
We used a direct analysis in this study, which investigates the presence or absence of 
MAP DNA in tissue.  We used two sequential rounds of nested PCR, on DNA preparations 
extracted directly from tissue samples, in order to substitute for Southern hybridization. The use 
of FISH with the aid of CSLM may provide physical evidence of the MAP bacterium in human 
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tissue and thus become essential in investigating any link between MAP and CD.  The FISH 
methodology employed in this study has been carefully optimized to provide significant 
sensitivity and specificity to the MAP bacterium. As shown in this study, spiking of normal 
tissue with MAP culture was clearly evident in the slides following our protocol (Fig. 2B). When 
coded tissue sections were investigated by FISH, MAP presence was easily reported. The data 
shown in Fig. 3 illustrates that MAP may be present in inflamed tissue, neighboring non-
inflamed tissue or in both. While accepting a possible sampling error during tissue collection and 
coding, MAP presence in inflamed tissue only in CD patients goes well with the general wisdom. 
Detection of MAP DNA in non-inflamed and not in the inflamed tissue samples may be 
explained by several scenarios including sampling error, poor inflamed tissue quality or low 
number and diversity in the distribution of MAP in the inflamed tissue.  Detection of MAP in 
both the inflamed and non-inflamed tissue samples suggests that MAP infiltrates host tissue as 
reported in animals with JD (36). Ultimately this confirms that MAP infection in human is 
systemic as we reported earlier when MAP was cultured in milk from CD patients (62).  This 
was also confirmed most recently in a new report where viable MAP was cultured from 
peripheral blood of 50% CD patients (64). On the contrary, MAP may be absent in some CD 
patients as we reported in this study where MAP DNA was not detected in tissue by either 
technique.  It is also of significant importance to report that MAP may be present in some 
patients with UC.  A study reported isolation of pleomorphic variable acid-fast organisms in over 
50% of UC patients (60).  Furthermore, Mishina et al reported that 2/4 UC tissue where MAP 
positive by RT-PCR (57).  In this study, two inflamed UC tissue had MAP DNA by nested PCR. 
We regret that FISH was not performed on the UC tissues samples due to the small size of tissue 
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samples.  MAP in tissue from UC patients may be explained as due to 1) IBD misdiagnosis 
which is well-acknowledged in the gastroenterology community, 2) a possible mixed infection as 
reported recently (9) or 3) a possible need for reclassification of IBD as one disease with two 
forms as seen in tuberculosis and leprosy (34). With regard to tissue from non-IBD patients, 
MAP was absent in tissue using FISH. 
Despite the need for visible number of MAP in the tissue in order to be visualized by 
CLSM, the majority of CD tissue contained MAP DNA compared to none in the non-IBD 
controls. Because of this concern related to the strength of MAP signal detected by FISH and 
recorded by CLSM in tissue, we employed two rounds of nested PCR on DNA extracts purified 
directly from same tissue samples. The PCR data clearly confirmed the data obtained by FISH.  
Further more, nested PCR detected MAP DNA in those samples with weaker MAP presence 
(83% of CD tissue contained MAP DNA by PCR compared to 67% by FISH).  The distribution 
of MAP in intestinal tissue is not homogenous which me explain the results where some CD 
tissue samples were positive by FISH and not by PCR or positive in the none-inflamed and not in 
the inflamed tissue sections despite our effort in performing multiple PCR analysis on different 
sections of the tissue and by extensive scanning of multiple slides by CSLM when sample size 
allowed.  The data clearly indicate that MAP is present in the majority of CD subjects compared 
to non-IBD controls thus providing more evidence towards the association of MAP with CD 
etiology. 
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CHAPTER THREE: POSSIBLE MYCOBACTERIAL ROLE IN 
FUNCTIONAL DYSREGULATION OF POLYMORPHONUCLEAR 
LEUKOCYTES AND PERIPHERAL BLOOD MONONUCLEAR CELLS IN 
CROHN’S DISEASE 
Introduction 
Pathogenic mycobacteria actively interfere with the cell-mediated immunity (CMI) of the 
host probably by dysregulating intracellular signaling pathways that further disrupt the network 
of cytokine signals that are supposed to organize, direct and modulate the immune response in 
order to eradicate the invading agent.  A genetic predisposition in the host may play a role in 
how the disease manifests itself.  In leprosy, individuals who produce a Th1 biased CMI reaction 
develop the contained tuberculoid form of leprosy, while those that produce a Th2 oriented CMI 
response develop the aggressive lepromatous form of the disease (6).  Although some evidence 
of this type of immune-modulation possibly by MAP in CD patients may exist (22), it is unclear 
as to what role this immune-modulation may take in the etiology of CD.  Mycobacterial heat 
shock proteins (HSP) are of interest due to their homology with human analogues and the 
enhanced production of antibodies and T cells which recognize mycobacterial HSPs in patients 
with CD (25, 54). While pathogenic bacteria such as adherent-invasive E. coli have been 
implicated in CD  (30), others like MAP have been vigorously debated. The pathogenesis of 
MAP would be expected to be similar to the pathogenesis of tuberculosis.  In fact, intestinal 
tuberculosis and CD may be clinically indistinguishable. M. tuberculosis, M. leprae and MAP 
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possess similar molecular components in their cell walls such as lipoarabinomannan which 
suppress antigenic responsiveness of PBL; inhibit antigen presentation; induce production of 
TNF-alpha; and inhibit IFN-gamma mediated macrophage activation (49). Bacterial lipoproteins 
via toll-like receptors (42) and IFN-gamma released from primed T-cells (8) and NK cells 
stimulate macrophages to produce the cytokine IL-12, which further stimulate both primed and 
naïve Th1 T-cells and also NK cells, inducing the release of TNF. TNF plays an important role 
in the pathogenesis of CD. Blocking TNF has been shown effective in reducing inflammatory 
symptoms in moderate to severe CD patients (73). IL-12 has been proposed as a marker of T-cell 
activation in sarcoidosis (47), and may be important in mediating the T-cell response in CD (69). 
Patients with tuberculosis often exhibit a negative PPD (purified protein derivative) skin test and 
a lack of T-cell responsiveness to mycobacterial antigen (anergy). In vitro stimulation of T cells 
with PPD results in the production of IL-10, IFN-gamma, and proliferation in PPD(+) patients, 
whereas cells from anergic patients produce IL-10 but not IFN-gamma and fail to proliferate in 
response to PPD.  In anergic patients, IL-10-producing T cells are constitutively present.  In this 
chapter, anergic responses as seen in tuberculosis, the role of MAP and the status of the cellular 
immune response in CD patients is investigated.  
Methods and Materials 
Patient Selection and Specimen source 
A total of 37 subjects consisting of 23 with CD, 3 with UC, and 11 healthy control 
individuals were included in this study. Table 3 shows the demographic information and type of 
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specimens obtained from each subject. In order to investigate bacterial infiltration in host tissue, 
multiple tissue samples in term of inflamed, non-inflamed and lymph nodes from individual 
subjects were sought and obtained when possible. Over all, a total of 43 surgically resected tissue 
specimens were obtained and analyzed in this study. Of which, 39 tissue samples (17 inflamed, 
15 non-inflamed and 7 lymph nodes) were obtained from 17 CD subjects, and 4 tissue samples 
(2 inflamed and 1 non-inflamed and 1 lymph nodes) obtained from two UC patients.  Full 
thickness small intestinal and colonic tissue specimens designated by a code were obtained at the 
time of surgery from consented participating subjects.  Informed consent was obtained from each 
subject in accordance with Internal Review Board (IRB) regulations at the University of Florida 
and Gainesville VAMC (Veterans Affair Medical Center). Additionally, a total of 31 peripheral 
blood samples (19 CD, 1 UC, and 11 healthy subjects) were analyzed. A volume of 30 ml of 
EDTA-whole blood was obtained from each subject when possible and shipped for analysis 
within 24 hours of collection (76).  A survey form with questions concerning family history of 
IBD, smoking status, ethnic background, fistulizing versus non-fistulizing disease, and 
medications history, especially in the past 4 weeks prior to giving clinical specimens was 
completed per subject (Table 3). 
Tissue Collection and Processing 
The tissue samples were catalogued blindly and referred to only by their assigned code. 
Macroscopic examination of the tissue samples was done immediately following the arrival of 
the tissue to the laboratory. Tubes containing marked inflamed tissue were processed separately 
from those marked as non-inflamed, lymph nodes or normal tissue. Each tissue was removed 
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from the transport tube and sectioned into three parts.  One part was processed for genomic DNA 
extraction followed by PCR analysis, second part was homogenized, decontaminated and 
processed for culture and the last part was flash frozen in liquid nitrogen. 
Peripheral Blood Withdrawal and Processing 
Fresh blood samples assigned with a code were immediately processed in a Biosafety 
Cabinet Class II as follows: PMN and PBMC were isolated using polymorphprep and 
lymphoprep density gradient separation medium following the manufacturer’s procedure 
(Greiner Bio One, Inc). Initially, blood samples were diluted 1:1 (v/v) with room temperature 
RPMI culture media (Invitrogen, CA).  For PBMC isolation, a volume of 4mL of diluted blood 
was layered on 4mL Lymphoprep solution in 15mL polypropylene tubes.  For PMN isolation, a 
volume of 5mL of the whole blood-RPMI (Roswell Park Memorial Institute) mixture was 
layered on 5mL polymorphprep solution in 15mL polypropylene tubes.  Tubes were centrifuged 
at 1,550 rpm and room temperature for 30 m. This results in formation of the density gradient 
interface, which is followed by isolation of bands containing PBMC or PMN. Purified cells then 
were transferred into sterile tubes for further use. 
Microbial Genomic DNA Extraction and PCR Analysis 
The PCR protocol for detection of the MAP IS900 DNA element was adapted from that 
kindly provided by Dr. J. Hermon-Taylor (St. George's Hospital Medical School, London, U.K.). 
Five hundred mg of fresh tissue was diced into fine pieces using sterile disposable scalpels. The 
tissue sample was re-suspended in 4.0ml mycobacterial lysis buffer (2mM EDTA, 400 mM 
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NaCl, 10 mM TrisHCl pH8, 100 ug/ml Proteinase K, and 0.6% SDS) and homogenized by an 
Omni Tip disposable generator probe (Fisher Scientific Pittsburgh, PA) for 1 m at 30,000 rpm. 
The tissue sample was incubated with shaking (200 rpm) at 37°C for 3 h, transferred to 
disposable FastPrep® lysing matrix B blue cap tube (Qbiogene, Carlsbad, CA), and ribolysed at 
6.5m/s-2 for 45 s by using a FastPrep® ribolyser (Qbiogene, Carlsbad, CA). The samples are 
placed on ice immediately for 15 m.  The DNA is then isolated by phenol/chloroform/isoamyl 
alcohol and ethanol precipitation. DNA pellet was dissolved in 250 µL TE buffer. The MAP 
specific IS900 DNA element was evaluated in triplicate using a nested primer PCR technique.  
Briefly, oligonucleotide primers P90 (5'-GTT-CGG-GGC-CGT-CGC-TTA-GG-3') and P91 (5'-
GAG-GTC-GAT-CGC-CCA-CGT-GA-3') were selected to amplify a unique 398 bp fragment of 
5' region of  IS900. To reliably detect MAP, AV1(5'-ATG-TGG-TTG-CTG TGT-TGG-ATG-G-
3') and AV2(5'-CCG-CCG-CAA-TCA-ACT-CCA-G-3')  were used for the nested PCR in the 
second  round  using the 398 bp amplified fragment as a template to amplify a 298 bp internal 
sequence. The PCR reaction mixture consists of 1×PCR buffer, 1.5mM MgCl2, 0.1mM dNTP, 
6% DMSO, 2µM primers, and 3.5u/50µl Platinum Taq polymerase (Invitrogen Carlsbad CA).  
Five µl of DNA template was used in first around PCR reaction in 50µl. A volume of 1µl of 
PCR product from first round was used in second round PCR in 50µl. The PCR cycling 
conditions were as follows: 95°C for 5 m, 40cycles of 95°C for 1m, 58°C for 1m, 72°C for 3 m; 
and a final extension of 5 m at 72°C.  The amplification product size was determined on an 
agarose gel. Some of the nested PCR products were gel purified and sequenced by the University 
of Florida DNA Sequencing Core facility confirming that the product was identical to the MAP 
IS900 sequence. Appropriate controls were included and analyzed side by side in every phase of 
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the experiments. This includes negative controls during genomic DNA extraction and the two 
rounds of PCR preparations.  MAP genomic DNA from a CD clinical isolate was used a positive 
control. However, the genomic MAP DNA was extracted independently and was analyzed in a 
separate Biosafety cabinet facility and using different supplies. 
In-vitro Phagocytosis Assay 
A clinical MAP strain Linda isolated from CD tissue was used in this study. MAP was 
cultured in 7H9 broth media supplemented with mycobactin J (Allied Monitor). Each MAP 
preparation of 1 x 107 CFU/ml was labeled by incubating with 100ug of FITC (Molecular 
Probes), for 30 m at room temperature. Following centrifugation at 13,000rpm for 5 m, 
supernatant was discarded, and labeled MAP cells were washed twice with PBS, pH 7.2. FITC-
labeled MAP was then suspended in 100uL of RPMI media.  The efficiency of in vitro 
phagocytosis of FITC-labeled MAP by PMN or PBMC was evaluated as follows. In triplicate, 
tubes with each has 1 x 106 of PMN or PBMC from 19 CD patients, 1 UC patient, and 11 healthy 
control subjects were incubated with 1 x 107 CFU of FITC-labeled MAP in the presence of 
100uL plasma from corresponding subject for 2 h at 37 oC followed by the addition of 100uL of 
0.2% trypan blue (Sigma, MO) in order to quench non-specific fluorescence. A volume of 200uL 
from each sample was aliquoted into a 96-well plate and the absorbance readings were measured 
at 485nm/535nm. Similar set up consisted of PMN, PBMC and plasma from a standard control 
was performed side by side with CD and healthy control subjects. The amount of internalized 
FITC-labeled MAP by cells from tested subjects was then compared to that from the standard 
control.  In order to study presence of plasma inhibitors, crossover experiments were performed 
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where PMN or PBMC from tested subjects were exposed to FITC-labeled MAP in the presence 
of 100uL plasma from a standard control and vice versa. 
Confocal Scanning Laser Microscopy Analysis 
Three different bacterial strains were used in this study.  A clinical MAP strain Linda 
isolated from CD tissue, Mycobacterium tuberculosis ATCC # 25177 (American Type Culture 
Collection, VA), and Escherichia coli strain TOP10 (Invitrogen, CA).  Localization of FITC-
labeled viable and dead bacterial cells was investigated in infected PMN by Confocal Scanning 
Laser Microscope (CSLM). Samples consisting of PMN from CD and control subjects infected 
in vitro with FITC labeled-bacterial cells were spotted on microscopic slides, mounted with 
antifade and then scanned by Zeiss CSLM. Slides were scanned under 40x objective lenses with 
oil.  All variables, such as photometric gain, photomultipler setting, pixel size, objective size, 
mounting medium, and numbers of scans to accumulation were recorded for each scan and 
images were documented. 
Cell Proliferation Assay 
Initially, the optimum PHA concentration was determined through titration. Aliquots of 1 
x 105 cells of PBMC from healthy subjects were plated and exposed to serial dilutions of PHA 
mitogen at final concentrations of 0.019, 0.078, 0.31, 1.25, 5, 20, and 80 ug/mL.  The microtiter 
plates were incubated at 37oC and 5% CO2 for 72h. PBMC were labeled with 
bromodeoxyuridine (BrdU, Roche Molecular Biochemicals, IN) and reincubated for additional 
24 h, and cell transformation was then measured using cell proliferation ELISA BrdU 
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commercial kit from Roche (Indianapolis, IN).  Briefly, the BrdU incorporation was measured by 
using a monoclonal antibody, anti-BrdU-POD, conjugated with peroxidase.  The immune 
complexes were detected by a substrate reaction and the reaction product was quantified by 
measuring the absorbance at 492nm in an ELISA Auto Reader II (Ortho Diagnostic Systems, 
Inc).  Solutions containing optimal concentration of PHA were prepared in sterile RPMI 1640 
(Invitrogen, CA).  The stocks were dispensed into sterile vials, in suitable volume for one assay, 
and held frozen at –20oC until use. 
Immunoreactivitiy of PBMC derived from CD and healthy subjects were evaluated as 
follows. In triplicates, PBMC at a final dilution of 1 x 105 cells/ well in a 96-well microtiter plate 
were mixed with plasma either from CD or control subjects. Mitogens and antigens investigated 
in this study included PHA (20ug/mL, Sigma, MO), Candida albicans extract (20 ug/mL; Greer 
Laboratories, NC), pokeweed mitogen (PWM, Sigma, MO) at 10 ug/mL and MAP purified 
protein derivative (PPD; 5ug/mL).  The MAP PPD was prepared in our laboratory by sonication 
of cell pellets from MAP culture grown to mid-log phase (approximately six weeks) followed by 
centrifugation at 16,000 rpm for 30 m, Cell debris were discarded and PPD supernatant was 
transferred to sterile tube and stored at -80 oC until use. The microtiter plates were incubated at 
37oC and 5% CO2 for 72h. PBMC were labeled with BrdU (Roche Molecular Biochemicals, IN) 
and reincubated for additional 24 h.  Cell transformation was measured in vitro using cell 
proliferation ELISA BrdU commercial kit from Roche (Indianapolis, IN) as described earlier. 
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Statistical Analysis 
Absolute values of one (positive) and zero (negative) were assigned to the observed data 
for each population and the variance was calculated by using the F-test for variances.  Data were 
normalized by multiplying each datum by the inverse of the variance of its group.  To evaluate 
the significance of the differences between each population we performed one-way ANOVA on 
the normalized data.  Differences with p values < 0.05 were considered significant. 
Results 
Detection of IS900 Gene of MAP by Nested PCR 
Two rounds of nested PCR using IS900-derived oligonucleotide primers were employed 
on 43 DNA extracts isolated directly from homogenized tissue specimens used in this study. The 
second round of PCR is considered the key step for the detection of MAP as indicated by the 
amplification of a 298 bp fragment. Multiple tissue specimens from different part of resectioned 
intestinal parts on individual subjects especially from CD patients were sought in this study in 
order to investigate infiltration of the MAP bacterium into the host tissue. Nested PCR detected 
MAP DNA in 21/43 all tissue samples; 19 CD tissue and 2 UC tissue. MAP infiltration in host 
tissue was confirmed following the detection of MAP DNA is neighboring non-inflamed and 
lymph nodes tissue.  Specifically, MAP DNA was detected in tissue from 15/17(88%) CD 
subjects and 1/2(50%) UC patients.  As shown in Fig. 6, MAP in 15 CD patients was detected in 
9 non-inflamed tissue (Fig. 6A lanes 2, 7, 11, 13, 20 and Fig. 6B lanes 4, 7, 10, 13), in 7 
inflamed tissue (Fig.6A lanes 8, 10, 15, 17, 19, 21 and Fig.6B lane 3) and in 4 lymph nodes 
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tissue (Fig.6A lane 26 and Fig 6B lanes 2, 5, 12). In UC patients, MAP DNA was detected in two 
tissue samples (Fig. 6B lanes 14 and 15) from 1 out of two patients. Representative of the 298 bp 
fragments from amplified DNA from MAP positive tissue samples were sequenced.  Following 
blast and alignment analysis of the nucleotide sequence amplified from positive tissue samples 
confirmed the amplification of the IS900 gene unique to MAP. 
Evaluation of PMN and PBMC Phagocytosis Uptake Mechanism 
In vitro phagocytosis of FITC-labeled MAP by PMN and PBMC derived from 19 CD 
patients was investigated and compared to those from 1 UC patient and 11 healthy controls. 
Initially, it was determined that FITC had no toxicity effect on the viability of MAP following a 
viability study where FITC-labeled MAP and unlabeled MAP were inoculated into 
mycobacterial broth culture media; both treatments gave similar growth properties.  The 
efficiency of phagocytic cells from CD patients to uptake and phagocytose viable FITC-labeled 
MAP was determined by the measurement of internalized fluorescence signal following 
quenching of unwashed and unphagocytosed FITC-labeled MAP.  The uptake of FITC-labeled 
MAP by subject’s PMN or PBMC in the presence of subject’s plasma was compared to the 
uptake of FITC-labeled MAP by PMN or PBMC from a standard normal control in the presence 
of plasma from the same standard normal control. Consequently, any suppression in 
phagocytosis uptake can be quantitatively determined. Whether the suppression is due to defect 
in the cells or to presence of cell-specific plasma inhibitors was determined following the cross 
over experiments using PMN, PBMC and plasma from a standard normal control.  Table 4 
summarizes the phagocytosis efficiency of viable MAP by PMN and PBMC and the effect of 
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possible cell-specific plasma inhibitors from blood samples of 31 subjects used in this study.   
PMN phagocytosis was suppressed in 13/19 CD subjects (68%) compared to none in controls 
(p< 0.001); suppression ranged from 6 to 97%. PBMC phagocytosis was suppressed only in 5/19 
(26%) of CD subjects; suppression ranged between 1 to 70%.  Following exposure of similar 
amount of PMN from CD patients and a standard normal control each to 107 CFU of FITC-
labeled MAP in the presence of their correspondence plasma, the amount of phagocytosed MAP 
by PMN is lower in CD patients compared to standard normal control. The quantitative 
measurement of phagocytosis suppression has been determined for all 31 subjects included in 
this study (Table 4).  
In order to investigate weather the suppression in phagocytosis uptake is due to defect in 
PMN or PBMC or to presence of cell-specific inhibitors that may interfere in the phagocytosis, a 
cross over experiment was designed. The subject’s cells incubated with FITC-labeled MAP were 
tested in the presence of standard control plasma. Accordingly, the uptake value for each cell 
type may remain similar if cell-specific plasma inhibitors are absent; the opposite is also true. As 
shown in Table 4, PMN-specific plasma inhibitors were detected in 9/19 (47%) CD subjects 
compared to none in controls (P<0.05). The negative effect of the presence of PMN-specific 
inhibitors in plasma from CD patients on healthy PMN phagocytosis has also been measured 
which ranged between 2 to 67% (Table 4). Plasma inhibitors specific to PBMC phagocytosis 
were mildly present in CD patients; present only in 3/19 (16%) CD subjects compared to none in 
controls.  All 13 (68%) CD subjects that have suppressed PMN phagocytosis were also positive 
for MAP DNA detection in tissue. 
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The localization of internalized viable and dead bacteria is graphically illustrated in 
figures 7, 8, 9 and 10 corresponding to phagocytosis by PMN from healthy, UC, and CD subjects 
respectively.  Viable and dead E. coli (Fig. 7A, 7B, 8A, 8B, 9A, 9B, 10A) and M. tuberculosis 
(Fig. 7C, 7D, 8C, 8D, and 9D) as well as dead MAP (Fig. 7F, 8F, 9F) localized similarly 
throughout the cytoplasm of PMN from all 3 different subjects.  In contrast, viable M. 
tuberculosis and viable MAP localized closer to the cytoplasmic membrane in phagosomes 
inside PMN isolated only from CD patients (Fig. 9C, 9E, 10B, 10C), but not from healthy (Fig. 
7C and 7E) or UC (Fig.8C and 8E) cells. 
T-Lymphocyte Proliferation 
The use of PHA, which is a plant mitogen, has been proven to be useful in investigating 
and assessing the overall function of lymphocyte responsiveness. PHA stimulates lymphocytes 
directly by mechanisms different than those used for specific antigen processing and presentation 
to lymphocytes. In this study, a final concentration of 20 ug/mL PHA mitogen following 72 h of 
incubation has been identified to provide optimum lymphocyte activation.  Therefore, all 
experiments including PHA were performed at this PHA concentration. 
In addition to PHA, the mitogen PWM and extracts from C. albicans and PPD from MAP 
were used to investigate the proliferative response of T-lymphocytes and its interaction with 
neighboring relevant cells such as B-lymphocytes and antigen presenting or other dendritric 
cells.  The proliferative response of PBMC isolated from CD and healthy control patients was 
quantitatively measured and compared to that of PBMC isolated from a standard normal control. 
Normal proliferative response was reported when PBMC from tested subjects matched or reacted 
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better than those from a standard normal control. Inactive proliferative response was reported 
when PBMC from tested subjects failed to react similarly to the standard normal control.  As 
shown in table 5, PBMC from 8/19 (42%) CD subjects showed dysfunctional proliferative 
response against PHA (ranged between 1 to 82%) compared to 1 in controls suggesting possible 
T-cell anergy.  More over, PBMC from 3 of these 8 CD subjects, reacted negatively against C. 
albicans extract suggesting a possible defect in antigen recall ability by activated monocytes.  
PBMC from the UC patient reacted normally to PHA and slightly to MAP PPD suggesting 
environmental mycobacterial exposure.  PBMC from the 11 CD subjects that reacted normally to 
PHA, 7 reacted strongly to MAP PPD suggesting pre-exposure to Mycobacteria, one reacted 
mildly to MAP PPD suggesting possible cross reactivity with environmental mycobacterial 
antigens and 3 did not react with MAP PPD suggesting lack of mycobacteria pre-exposure. Of 11 
healthy control subjects, 10 (91%) reacted normally to PHA.  Mild reactivity to MAP PPD due to 
cross reactivity with environmental mycobacterial antigens was detected in 2 healthy control 
subjects. PWM provided limited information in this study. Over all 15 out of 19 (78%) CD 
subjects either indicated possible T-cell anergy or MAP pre-exposure compared to detection of 
MAP DNA in tissue from 15/17 (88%) CD subjects. 
Discussion 
In this study MAP was used to evaluate the phagocytic function of PMN obtained from 
CD and UC patients undergoing bowel resections.  The results shown in Table 4 reveal a 
significant decrease in the uptake of FITC-labeled MAP by PMN from CD subjects compared to 
those from controls. This may suggest an original defect in the innate immune response of CD 
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patients or it may reflect an acquired, secondary defect in the immune response caused by the 
disease itself. Both possibilities may co-exist, especially if a genetic trait predisposes to an 
infection with an etiologic microbe. Other pathogenic bacteria such as members of Brucella are 
known to interfere with phagosome/endosome trafficking as a survival strategy to avoid immune 
destruction. This observation is similar to events that occur in M. tuberculosis-infected immune 
cells where the pathogen interferes with signals and dysregulates the immune system so that an 
effective response is not initiated. Geijtenbeek et. al (28) demonstrated that M. tuberculosis binds 
to DC-SIGN (dendritric cell-specific intracellular adhesion molecules, ICAM, intracellular 
adhesion molecules) to interfere with DC maturation and signaling that further dysregulates T-
cell function and results in an ineffective cell mediated immune response against the bacterium. 
The immature DC’s are still able to present MHC-antigens but lack the required co-stimulatory 
molecules needed to cause a robust and properly coordinated Th1 response.   
In this study, Figures 9E and 10C demonstrated that viable MAP was localized near the 
inner side of the cytoplasmic membrane away from the center of the cytoplasm of an in vitro 
infected PMN from CD patients.  This correlates with viable M. tuberculosis (Fig. 9C and 10B) 
where there is a visible phagocytic vacuole containing bacteria protruding from the cell 
membrane.  We did not observe the same pattern with cells from either the healthy or UC 
controls where bacteria localized throughout the cytoplasm indicating that is being processed and 
destroyed by the immune system of these individuals.  This finding suggests that CD results from 
a complex interplay of factors including the genetic make-up of the host.  As polymorphisms 
within the NOD2 gene have been associated with increased CD susceptibility (68), other 
undiscovered genes may be responsible for a genetic defect in PMN phagocytosis of CD 
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patients.  This finding is similar to the facts discussed earlier regarding host-agent interaction 
reported in Brucellosis and tuberculosis diseases. This data graphically confirm an earlier report 
which proposed that MAP resists intracellular killing by residing within a phagosomal 
compartment that retains the characteristics of early phagosomes and resists maturation into 
functional phagolysosomes (48).  
In lymphocytes derived cells from CD patients, transformation responses to some 
antigens assess their degree of prior sensitization. Since mitogens directly stimulate lymphocytes 
by bypassing macrophage presentation, decreased mitogen stimulation (PHA) indicated a global 
non-reactivity in the patient’s lymphocytes.  But anergy is usually associated with a specific 
antigen, so it is expected to be observed as a decreased response to a specific antigen.  As shown 
in Table 5, we observed T-cell anergy due to failure to respond normally to PHA in 8 out of the 
19 CD subjects.  We also observed strong reactivity to PPD from MAP in 7 out of 11 CD 
subjects who responded normally to PHA.  The observation of T-cell anergy in blood samples 
from significant CD cases compared to none in healthy control and the fact that T-cell from CD 
patients have shown to be presensitized to MAP clearly suggest a possible MAP involvement in 
some CD cases.  These findings are so similar to immunological events occur in tuberculosis.  
The data presented shows a possible role of MAP in CD pathogenesis and may be helpful 
toward choosing the appropriate treatment protocol for this complex disease by knowing the 
status of the immune response in CD patients. 
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 CHAPTER FOUR: ANALYSIS OF GENE EXPRESSION IN BUFFY 
COATS FROM CROHN’S DISEASE PATIENTS 
Introduction 
DNA microarray technology has become the most widely used technique for global 
expression studies.  Since the first microarray experiment was described (75), it has provided an 
unprecedented opportunity to generate gene expression data on a genomic scale.  Medical 
application of microarray technology is very limited since gene expression varies normally.  A 
study done by Whitney et al. provides a strong support for the feasibility of using gene 
expression patterns in peripheral blood as a basis for detection and diagnosis of disease in human 
patients.  They showed that the degree of variation in gene expression in the blood of healthy 
individuals is smaller than the one seen in the individuals who had cancer or infection (81).  In 
this chapter, we used microarray technology to identify the expression profile of genes to be 
involved that are required, or have a role in the immune response of CD patients.   
Methods and Materials 
Patient Selection and Specimen Source 
A total of 11 subjects consisting of 8 healthy controls, 2 CD and 1 UC patients were 
included in this study.  Informed consent was obtained from the subjects in accordance with 
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Institutional Review Board regulations at the University of Florida, Gainesville VAMC, and the 
University of Central Florida.  The diagnosis of CD or UC was established on standard clinical, 
endoscopic, histologic, and radiographic criteria (7). One whole blood sample drawn into a K
2
-
EDTA sterile vacutainer® tube was collected from each subject.  All samples were coded and a 
self-reported health status and medication use of each subject was recorded using a standardized 
questionnaire in order to minimize variables such as age, gender, and medication interference. 
Peripheral Blood Withdrawal and Processing 
The samples were immediately processed in a class II biosafety cabinet.  For buffy coat 
extraction, the tubes were centrifuged at 3000 rpm for 10 min. The buffy coat layer from each 
tube was transferred into a RNase-free tube containing 800 uL of RNA later solution (Ambion, 
CA) and kept refrigerated until processing.   
Microarray Analysis 
The protocols used for this study were obtained from those developed for the analysis of 
human microarrays (38). 
Array Chip:   
A 30,000-gene clone set made of PCR-amplified cDNA clones that represent unique 
human transcripts within the Expressed Sequence Taq (EST) from UniGene 
(http://www.ncbi.nlm.nih.gov/UniGene/) at the National Center for Biotechnology Information 
and The Institute for Genomic Research (TIGR) Human Gene Index (HGI) 
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(http://www.tigr.org/tigr-scripts/tgi/T_index.cgi?species=human).  The TIGR protocol assembles 
the ESTs within clusters to produce tentative human consensus (THC) sequences.  Purified PCR-
amplified genes were arrayed by using the Molecular Dynamics Generation III Array Spotter.  
This arrayer deposits nanoliter volumes of samples at high density onto aminosilane coated glass 
slides.   
Total RNA Isolation:  
Total RNA was extracted from freshly isolated buffy coats, PMN and PBMC by using a 
modified protocol from the RNAqueous –4PCR kit (Ambion, CA). 
RNA labeling and hybridization:   
Total RNA was used as a template for random-primed first-strand cDNA synthesis in the 
presence of amino-allyl-dUTP (Sigma, MO) during reverse transcription, then the purified 
products were conjugated to fluorescent dyes.  A pooled of total RNA extracted from the 8 
healthy individuals was used as a reference RNA sample to provide a common internal reference 
standard for comparison.  Hybridization reactions were conducted as described in The Institute 
for Genomic Research (TIGR) standard operating procedures 
(http://www.tigr.org/tdb/microarray/protocolsTIGR.shtml). 
Data Collection:   
Hybridized slides were scanned using the Axon GenePix 4000 microarray scanner, and 
the independent TIFF images from each channel were analyzed using TIGR Spotfinder 
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(http://www.tigr.org/software/tm4/spotfinder.html) to assess relative expression levels. Spots 
with lower intensity than local background were assigned 0 values.  Spots with intensities less 
than 1.5 times the local background level in either of the two channels were eliminated before 
data normalization to remove unreliable low-intensity spots. 
Data Normalization and Data Analysis:   
Normalization is necessary to adjust for differences in labeling and detection efficiencies 
of the fluorescent labels and for differences in the quantity of starting RNA.  Data was 
normalized using a local regression technique, LOWESS (Locally Weighted Scatterplot 
Smoothing), using the MIDAS software tool (http://www.tigr.org/softlab, TIGR).  All calculated 
gene expression ratios were log2-transformed, and differentially expressed genes at the 95% 
confidence level for each reference set were determined by assuming the log2 ratios for each data 
set form a normal distribution, and selecting genes with log2 (ratio) values > 1.96 standard 
deviations from the mean (2).  This filtration of the significantly expressed genes was conducted 
using MIDAS, and the resulting lists of the genes were examined further by cross comparison 
between experiments using TIGR MeV (http://www.tigr.org/softlab, TIGR) with EASE 
(Expression Analysis Systematic Explorer), which allows the biological interpretation of gene 
clusters. 
Results 
To explore and characterize the gene expression profiling within CD and UC disorders, 3 
total RNA samples from 1 UC and 2 CD patients, were analyzed against a reference sample of 
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pooled total RNA from 8 healthy individuals.  Samples were analyzed by comparative 
hybridization to DNA microarrays containing 30,000 elements representing unique human 
transcripts. 
We found that 17% (5630 genes) of the total number of genes was differentially 
expressed in both IBD disorders compared to the reference pooled sample.  These genes were 
distributed mainly within four biological themes (Fig. 11) classified as cellular processes (38%), 
physiological processes (26%), intracellular genes (18%), and genes involved in metabolism 
(18%).  We focused our investigation primarily on genes directly related to the immune response 
since CD and UC are complex diseases characterized for chronic intestinal inflammation. Of the 
5630 genes differentially expressed in the experimental samples, 238 genes belonged to genes 
involved in the immune response (Fig.12).  
As shown in Table 6, seven genes where common to both forms of IBD with variation in 
the level of gene expression where 6 genes were downregulated and 1 gene was upregulated.  
Two downregulated genes corresponded to the same biological description (GenBank numbers 
W79396 and AI262976).  These 2 genes contain a C2h2 zinc finger and belong to one of the 
largest gene families in the human genome. These proteins are involved in transcriptional 
regulation and are quite conserved throughout evolution (2).  Another downregulated gene was 
the NKG2E (GenBank number W93370) that plays a role as a receptor for the recognition of 
MHC class I molecules by NK cells and some cytotoxic T-cells (31).   The CD160 antigen 
precursor (GenBank number AA463248) was also found to be downregulated (1).  The 
expression of the Secreted phosphoprotein 1 (GenBank number AA775616) was downregulated.  
This protein acts as a cytokine involved in enhancing production of interferon-gamma and 
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interleukin-12 and reducing production of interleukin-10 and is essential in the pathway that 
leads to type I immunity (50). Carbohydrate sulfotransferase 2 or CHST2 (GenBank number 
AA682637) is a Golgi membrane-bound sulfotransferase that catalyzes the transfer of sulfate to 
position 6 of a N-acetylglucosamine (GlcNAc) residue. Its mouse homolog has been involved in 
the biosynthesis of 6-sulfosialyl Lewis X antigen, which is a component of L-selectin ligands 
(51).  The only upregulated gene between UC and CD samples was the Toll-like receptor 4 
precursor (GenBank number AI371874), which is highly expressed in PBL and mediates the 
innate immune response to bacterial lipopolysaccharide (LPS) (56).   
Eight genes were found to be either upregulated or downregulated in CD or UC only 
(Table 7).  Within the unique genes, we found a protein encoded by the gene TRIM22 (GenBank 
number AA083407), which is induced by interferon and it has been involved in the mediation of 
interferon's antiviral effects (79).   The expression of the small inducible cytokine A18 precursor 
(CCL18) or macrophage inflammatory protein (MIP-4) was upregulated in UC patients, and 
downregulated in CD patients.  This cytokine is a chemotactic factor that attracts naive T 
lymphocytes toward dendritic cells and activated macrophages in lymph nodes, but not 
monocytes or granulocytes (41).  Interestingly, another gene with similar function to CCL18, 
Lymphotactin precursor (XCL1) (GenBank number AI298976), was also found to be 
downregulated in CD patients only.  A gene that codes for an integral membrane protein which is 
a probable mediator of viral effects on B lymphocytes (GenBank number AI123732) was found 
to be downregulated in CD patients.  This gene is predicted to encode a G protein-coupled 
receptor.  Expression of this gene was detected in B-lymphocyte cell lines, but not in T-
lymphocyte cell lines.  The function of this gene is unknown (4).  The expression of the small 
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inducible cytokine A3 precursor (CCL3) or Macrophage inflammatory protein 1-alpha (MIP-1-
alpha) (GenBank number R47893) was downregulated in CD patients.  This cytokine is one of 
the major HIV-suppressive factors produced by CD8+ T cells (13).  Lymphotoxin-beta receptor 
(GenBank number AA454646) is a member of the tumor necrosis factor (TNF) family of 
receptors.  Activation of this protein can trigger apoptosis (84). We found of great significance 
the differential expression of the gene that codes for IFNGR1 since defects in this gene have 
been directly linked to susceptibility to mycobacterial infection (15, 44, 45).  The expression of 
this gene was downregulated in CD patients only.   
Discussion 
Previous studies showed that large ZAS proteins with two separate C2H2 zinc finger 
pairs, independently bind to specific DNA sequences, including the kappaB motif. These 
proteins associate with a TNF receptor- factor to inhibit NF-kappaB- and JNK/ SAPK-mediated 
signaling of TNF-alpha (83).  This might explain why TNF-alpha plays an important role in CD 
pathology.  Since its regulation is altered, the TNF-alpha signaling pathways are constantly 
active increasing the inflammation process in CD patients.  Natural killer cells are being found to 
play a primary role in preventing and removing cancer cells in the body, and removing many 
types of viruses (31).  CD160 antigen is specific for NK cells and its expression was also 
downregulated, adding to a possible defective NK cells function. This may be linked to the 
secondary viral infections that few IBD patients develop.  
In a previous study, a mouse cDNA encoding GlcNAc-6-O-sulfotransferase was cloned 
and was identified as homolog of the human CHST2.  When expressed in mammalian cells, the 
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mouse protein exhibited GlcNAc-6-O-sulfotransferase activity and was involved in the 
biosynthesis of 6-sulfosialyl Lewis X antigen, which is a component of L-selectin ligands. The 
L-selectin system is implicated in inflammatory leukocyte trafficking in both acute and chronic 
settings.  By blocking 6-sulfosialyl Lewis X antigen in human lymphoid organs, the L-selectin 
dependent adherence of lymphocytes to high endothelial venules (HEV) is affected (70).  If 
human CHST2 has a similar function as its mouse homolog, one can speculate that the process of 
recircularization of lymphocytes from the blood into lymphoid organs ("homing") and back to 
the blood could be affected in these patients. 
It is interesting to find upregulation in the expression of TLR4 indicating the presence of 
bacterial LPS in both disorders. TLR4 acts via TRAF6 in the activation of NF-kappa-B, cytokine 
secretion and the inflammatory processes frequently observed in these patients.  The fact that the 
expression of the Staf-50 or TRIM22 encoded protein was downregulated in UC patients only 
suggests that these patients may be more vulnerable to a secondary viral infection than CD 
patients.   
The expression of CCL18 or MIP-4 and Lymphotactin precursor (XCL1) was 
downregulated only in CD patients.  This may add to the ineffective process of antigen 
presentation in CD, but not in UC.  A study showed that the lymphotoxin-beta receptor mediates 
cell death in HeLa cells (84).  The gene that encodes this protein was upregulated in UC patients 
only, which might explain the reduced number of immune cells in tissue lesions compared to the 
ones seen in CD. 
IFNGR1 encodes the ligand-binding chain (alpha) of the IFN-gamma receptor.  It is 
known that defects in IFNGR1 are a cause of familial disseminated atypical mycobacterial 
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infection and disseminated bcg infection.  Patients suffering from this deficiency have an 
immunologic defect predisposing them to infection with mycobacteria (15, 44, 45).  Surprisingly, 
we found downregulation of IFNGR1 only in CD samples, but not in UC samples.  This 
correlates with the proposed theory as Mycobacterium avium subspecies paratuberculosis 
(MAP) being the causative agent of CD (11, 40, 53, 62).  
 In summary, we used cells from a simple human tissue (blood) to investigate the 
variation in gene expression within two human disorders.  This work supports the establishment 
of two different IBD disorders with different etiological processes and strengthens the 
mycobacterial etiology of CD. 
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 CHAPTER FIVE: GENERAL DISCUSSION 
Investigating the association of MAP or other agents in CD etiology remains a source of 
a major debate among investigators.  The data reported by those supporting the association of 
MAP with CD etiology is credible and their argument has merit.  However, it is also responsible 
to keep an objectivity regarding other studies, which reported the possible involvement of other 
factors in the etiology of Crohn’s syndrome. Variation in the selection and use of methodology is 
the underlining cause for the mixed outcome in these studies.  The debate may vary with regards 
to the percentage of CD cases associated with MAP. Attempts to culture MAP from tissue 
samples from CD patients have been tried in the past.  The outcome depended significantly on 
the technology used and the specimen selection and processing.  In our laboratory we reported 
previously the isolation of MAP from full-thickness tissue samples obtained from CD patients 
following short term incubation in mycobacterial growth indicator tube (MGIT) culture media 
(76). Using the same culture media, we isolated MAP from breast milk from two CD lactating 
mothers (62). In both reports, IS900-based PCR was employed to verify MAP presence in the 
culture. This was recently confirmed in Hermon-Taylor laboratory where 92% of intestinal 
biopsies were positive for MAP compared to 26% in controls (7).  The nature of MAP in CD 
tissue is significantly different from those in animals with JD (64).  Therefore, using technology 
designed for isolation of bacillary form of MAP as in JD sources may not be applicable to that in 
human with CD.  That alone will play a major factor in the outcome of the study.  There is a 
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possibility that exposure to MAP could occur through environmental fecal contamination or from 
the milk or blood from JD-infected animals (32, 78).   
Phagocytosis is an extremely important process for the recognition, ingestion, and 
digestion of antigen(s) in the host defense mechanism.  As described by Hornef et al., there are 
several mechanisms that bacteria use as a defense against phagocytes (42).  These include 
apoptosis, inhibition of antigen uptake, bacterial escape from the endosome, interference with the 
maturation of the immune cells and/or their phagosomes, and subcellular localization of defense 
factors. It is worth mentioning the mechanisms by which a well-known intracellular pathogen, 
Mycobacterium tuberculosis, suppresses antigen presentation and T-cell activation.  M. 
tuberculosis inhibits phagosomal maturation by depleting H+ ATPase molecules from the 
vacuolar membrane.  This leads to reduced acidification and allows intracellular survival and 
growth.  This correlates with a combination of inadequate clearance of MAP by PMN from CD 
patients and impaired macrophage function as shown in this study.   
For many years immunosuppressants and/or antibiotics were used to treat CD (27). Given 
the historical confusion over the etiology and pathogenesis of the syndrome, the approach for 
treating the disease by suppressing inflammatory symptoms with immunosuppressants can be 
regarded as random at best – and at worse – detrimental.  Most therapeutic strategies have tried 
to suppress the overactive adaptive immune response.  The use of random, single agent antibiotic 
regimens used in the past may or may not have been helpful. Recently, another approach has 
been proposed that is based on the stimulation of the innate immune system with growth factors 
(19, 21).  GM-CSF was administered to 15 CD patients. Twelve patients showed a decrease in 
the CD activity index, and 8 achieved clinical remission. This suggests that the problem in CD 
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does not lie in an excessive immune response against self-antigens as argued by the autoimmune 
theory.   On the contrary, it suggests that one major factor involved in CD is an immune 
deficiency, either primary or secondary or both.  CD may be related to the inability of the 
immune system to defend against a microbial attack and once the mycobacterial infection is 
established, further insults to the immune system caused by the infection itself exacerbate the 
problem. 
The downregulation in the expression of the IFNGR1 in CD patients only is a strong link 
to the proposed mycobaterial etiology of Crohn’s disease. It also supports why UC patients 
having MAP exposure don’t develop the same clinical manifestations as CD patients or don’t 
respond to anti-mycobacterial treatments. 
In a chronic disease such as Crohn’s disease, the clinical status and prognosis of the 
disease depends on the balance between host factors and the pathogenicity of the bacterium.  
MAP may cause disease by its ability to resist intracellular killing by macrophages and multiply 
within macrophages.  Furthermore, the ongoing immune processes are influenced by parameters 
such as the immunological status, genetic makeup, and the environment of the host.  Taken all 
together, the data presented in this work adds more evidence towards the association of MAP 
with CD etiology.  It is important to know that in order to understand the problem in its proper 
perspective, it is essential to take into account the immunological responses of the host and the 
ways and means by which MAP overcomes the host immune response. 
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Table 1:  Demographic Information and Type of Specimens used in Chapter Two 
_____________________________________________________________________________________________   
        SUBJECT                       DISEASE        TISSUE SPECIMEN 
________________    ________________________________________________ _____________________ 
SEX  AGE  DIAGNOSISa        SITEb     DURATION  TYPEc  SURGERIES  IMMUNOSUPRESSION            INFLAMEDd  NON-INFLAMED  
_____________________________________________________________________________________________ 
   F    25          CD         Colon  4y F 2  6MP        X  X 
  M    26          CD      Small Bowel   9y          I 1  Steroids        X  X 
   F    68          CD      Bowel-Colon  42y      F+S 3  None        X  X 
   F    56          CD      Bowel-Colon  11y        S 1  6MP        X  X 
  NA  NA        CD      Small Bowel   20y        S  1  Steroids        X  X 
  M    60          CD         Colon    5y         I   0  Steroids        X  X 
  M    43          CD      Small Bowel   14y      I+F+S    1  Steroids        X  X 
   F    39          CD            NA  19y      I+F+S    3  Steroids, Infliximab   X  X 
   F    54          CD      Bowel-Colon    4y         S    2  Steroids, 6MP        X  X 
  M    21          CD      Small Bowel   12y        S 1  Steroids        X  X 
  M    25          CD      Bowel-Colon   8y         F+S 2  Steroids, 6MP            X  X 
   F    40          CD      Bowel-Colon   1y          S 1  Steroids, Infliximab   X  NA 
  M    54          UC            NA            NA        NA 1  None        X  NA 
  M    42          UC            NA            NA        NA 1  None        X  NA 
   F    79     non-IBD         NA            NA       NA 1  None        NA  X 
 NA  NA    non -IBD        NA            NA        NA 1  None        NA  X 
   M    64     non-IBD        NA   NA        NA 1  None        NA  X 
   M    73     non-IBD        NA   NA        NA 2  None        NA  X 
    F    76     non-IBD        NA             NA        NA 1  None        NA  X 
   M    71     non-IBD        NA    NA        NA 1  None        NA  X 
____________________________________________________________________________________________  
aCD = Crohn’s disease; UC = Ulcerative colitis; non-IBD = non-inflammatory bowel disease subjects  
M= male; F = female; 6MP = 6-mercaptopurine; bNA = not available 
cS = stricturing state; F = fistulizing state; I = inflammatory state 
dX = Tissue specimen available 
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Table 2: Detection of MAP DNA in tissue by FISH using CSLM and nested PCR 
_____________________________________________________________________________________________   
Code Diagnosis            Inflamed Tissue   Non-Inflamed Tissue         Either Tissue 
____     _________           _______________________ __________________ __________________ 
        FISH   PCR  FISH        PCR FISH            PCR 
_____________________________________________________________________________________________ 
R2      CD     Positive Negative Positive       Negative Positive           Negative 
R7      CD     Positive Positive  Positive       Positive Positive           Positive 
R8      CD     Positive Positive  Positive       Negative Positive           Positive 
R13      CD     Negative Negative Positive       Positive Positive           Positive 
R14      CD     Positive Negative  Negative     Positive Positive           Positive 
R15      CD     Negative Positive  Negative     Negative    Negative         Positive 
R19      CD     Negative Positive  Negative     Positive Negative         Positive 
R20      CD     Positive Positive  Negative     Negative Positive          Positive 
R21      CD     Negative Negative Negative     Negative         Negative         Negative 
R24      CD     Positive Positive  Negative     Positive Positive          Positive 
R28      CD     Negative Negative Negative     Positive Negative         Positive 
R35      CD     Positive Positive        NA       NA  Positive           Positive 
_____________________________________________________________________________________________  
Total      12       7/12(58%) 7/12(58%) 4/11(36%)  6/11(55%) 8(67%)           10(83%) 
_____________________________________________________________________________________________ 
R11 UC         NA  Positive  NA        NA                   NA                 NA 
R25 UC        NA  Positive  NA        NA                   NA                 NA 
_____________________________________________________________________________________________  
Total    2    2(100%)     NA        NA                   NA        2(100%)                  
R3 non- IBD                    NA                  NA          Negative     Positive Negative         Positive 
R5 non- IBD                    NA                  NA               Negative     Negative Negative         Negative 
R10 non- IBD                    NA                  NA               Negative     Negative Negative         Negative 
R16 non- IBD                    NA                  NA                    Negative      Negative Negative         Negative 
R18 non- IBD                    NA                  NA                    Negative      Negative Negative         Negative 
R30 non- IBD                    NA                  NA                    Negative      Negative Negative         Negative     
___________________________________________________________________________________________  
Total    6      0(0%)        1(17%)    0(0%)             1(17%)  
CD: Crohn’s disease; UC: ulcerative colitis, NA: not available, Non-IBD: non-inflammatory bowel disease 
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Table 3: Demographic Information and Type of Specimens used in Chapter Three 
         Subject                             Disease            Specimen 
Code    Sex    Age    Diagnosisa           Siteb         Duration  Typec   Inflamed  Non-Inflamed  Lymph  Bloodb  
                                        Tissueb          Tissueb       Nodeb
 R1        M      50          CD           Bowel-colon       7y          S                X       X         NA         NA 
 R2        F       25          CD                  Colon           4y          F                 X                  X          X           X 
 R4        M      29          CD           Bowel-colon      16y          I               NA               NA         NA          X 
 R7        M      26          CD           Small bowel        9y          I                X                  X            NA          X 
 R8        F       68          CD            Bowel-colon      42y        F+S              X                  X         NA          X 
 R9        M      39          CD                    NA             NA         S               NA               NA         NA          X 
 R1 3     F       56          CD            Bowel-colon       11y        S                X                  X         NA          X 
 R1 4     NA   NA         CD           Small bowel       20y         S                 X       X          X           X 
 R1 5     M      60          CD                 Colon            5yr          I                X       X         NA          X 
 R1 7     M      NA         CD           Bowel-colon      11y         S                X                  X         NA          X 
 R1 9     M      43           CD           Small bowel       14y      I+F+S           X                 X         NA          NA 
 R20      F       39           CD                   NA             19y       I+F+S           X                 X         NA          X 
 R21      F       54           CD            Bowel-colon      4y          S                X                 X         NA          X 
 R22      F       31           CD                Colon            25y          I                X                 X          X           NA 
 R23      F       21           CD            Bowel-colon      8y          S                X                 NA           X           NA 
 R24      M      21           CD             Small bowel     12y         S               X                  X           X           X 
 R27      M      40           CD            Bowel-colon     14y         S               X                  X           X           X 
 R28      M      25           CD            Bowel-colon      8y         F+S            X                  X           NA        X 
 R34      F       22           CD            Bowel-colon      3y        I+F+S          NA               NA           NA        X 
 R35      F       40           CD            Bowel-colon      1y           S              X                  NA           X           X 
 R37      F       50           CD            Bowel-colon     10y       I+F+S         NA               NA           NA         X 
 R38      F       37           CD                     NA             NA         NA           NA              NA             NA         X  
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         Subject                             Disease            Specimen 
Code    Sex    Age    Diagnosisa           Siteb         Duration  Typec   Inflamed  Non-Inflamed  Lymph  Bloodb  
                                         Tissueb          Tissueb       Nodeb
R39      M      36           CD                  Colon          12y         S                NA              NA           NA        X 
C1        M      40        Healthy               NA             NA         NA            NA     NA        NA          X 
 C2         F      28        Healthy               NA              NA        NA            NA     NA        NA          X 
 C3        M      30        Healthy               NA              NA        NA            NA     NA        NA          X 
 C4         F      30        Healthy               NA              NA        NA            NA     NA        NA          X 
 C5        M      46        Healthy               NA              NA        NA            NA     NA        NA          X 
 C6        M      32        Healthy               NA              NA        NA            NA     NA        NA          X 
 C7         F      29         Healthy               NA             NA         NA            NA     NA        NA          X 
 C8        M      31         Healthy              NA              NA         NA            NA     NA        NA          X 
 C9        M      26         Healthy              NA              NA         NA           NA     NA        NA          X 
 C10      F     24          Healthy               NA              NA          NA           NA     NA        NA          X 
 C11      F     27          Healthy               NA              NA          NA           NA     NA        NA          X  
  R11      M     64              UC                NA              NA          NA            X      X        NA         NA 
  R25      M     42              UC               NA               NA          NA            X      NA         X           NA 
  R62      F       41             UC               NA               NA          NA            NA      NA         NA          X 
_____________________________________________________________________________________________ 
a-CD:Crohn’s disease, UC: Ulcerative colitis, Healthy subjects 
b-NA: not applicable or not available, X: specimen available 
c-S: structuring state, F: fistulizing state, I: inflammatory state 
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Table 4: In Vitro Evaluation of Phagocytic Uptake of MAP by PMN and PBMC 
_______________________________________________________________________ 
Code Diagnosis PMN Phagocytosis of  FITC-MAP               PBMC Phagocytosis of FITC-MAP 
   Uptakea  Plasma Inhibitorsb Uptake  Plasma Inhibitors 
   _________________________________      ____________________________ 
R2 CD  Suppressed (-23%) Absent  Suppressed (-6%) Absent 
R4 CD  Normal   Absent  Suppressed (-13%) Absent 
R7 CD  Suppressed (-21%) Present (-27%) Normal   Absent 
R8 CD  Suppressed (-24%) Present (-2%) Normal    Absent 
R9 CD  Suppressed (-9%) Absent  Normal   Absent 
R13 CD  Suppressed (-35%) Absent  Suppressed (-1%) Absent 
R14 CD  Suppressed (-7%) Present (-2%) Normal   Absent 
R15 CD  Normal   Present (-7%) Normal   Absent 
R17 CD  Normal   Absent  Normal   Absent 
R20 CD  Suppressed (-97%) Present (-49%) Normal   Absent 
R21 CD  Suppressed (-42%) Absent  Normal   Absent 
R24 CD  Suppressed (-6%) Present (-47%) Normal   Absent 
R27 CD  Suppressed (-32%) Present (-13%) Normal   Absent 
R28 CD  Suppressed (-56%) Present (-10%) Suppressed (-70%)  Present (-23%) 
R34 CD  Normal   Absent  Normal   Absent 
R35 CD  Suppressed (-79%) Present (-67%) Normal      Present (-16%) 
R37 CD  Normal   Absent  Normal   Absent 
R38 CD  Normal   Absent  Normal   Absnet 
R39 CD  Suppressed (-11%) Absent  Suppressed (-12%)   Present (-5%) 
C1 Healthy  Normal   Absent  Normal   Absent 
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Code Diagnosis PMN Phagocytosis of  FITC-MAP                PBMC Phagocytosis of FITC-MAP 
   Uptakea  Plasma Inhibitorsb Uptake  Plasma Inhibitors 
   _________________________________      ____________________________ 
C2 Healthy  Normal   Absent  Normal   Absent  
C3 Healthy  Normal   Absent  Normal   Absent 
C4 Healthy  Normal   Absent  Normal   Absent 
C5 Healthy  Normal   Absent  Normal   Absent 
C6 Healthy  Normal   Absent  Normal   Absent 
C7 Healthy  Normal   Absent  Normal   Absent 
C8 Healthy  Normal   Absent  Normal   Absent 
C9 Healthy  Normal   Absent  Normal   Absent 
C10 Healthy  Normal   Absent  Normal   Absent 
C11 Healthy  Normal   Absent  Normal   Absent 
R62    UC  Normal   Absent  Normal   Absent 
a-Phagocytosis uptake was evaluated by exposing subject’s PMN and PBMC to FITC-labeled MAP in the presence 
of plasma from the subject compared to a standard healthy control.  Percentage of suppression was reported when 
phagocytosis uptake by subject’s cells was lower than that of the standard healthy control. 
b-Plasma inhibitors specific for PMN or PBMC phagocytosis were measured by cross-over experiments incubating 
the plasma from each subject with cells from the standard healthy control and FITC-labeled MAP.  These values 
were compared to those corresponding to the standard healthy control in the presence of plasma without inhibitors.    
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Table 5: Evaluation of PBMC Proliferative Response 
Code Diagnosisa PHAb   Candida albicans c  PWMd   MAP PPDe 
R2 CD  Inactive (-1%) Normal   Normal  No response 
R4 CD  Normal  Normal   Normal  Strong 
R7 CD  Inactive (-26%) Inactive (-5%)  Normal  No response 
R8 CD  Inactive (-82%) Normal   Inactive (-27%) No response 
R9 CD  Inactive (-3%) Inactive (-27%)  Normal  No response 
R13 CD  Normal  Normal   Normal  No response 
R14 CD  Normal  Normal   Normal  No response 
R15 CD  Normal  Normal   Normal  Strong 
R17 CD  Inactive (-3%) Inactive (-2%)  Normal  No response 
R20 CD  Normal  Inactive (-19%)  Normal  Strong 
R21 CD  Inactive (-4%) Normal   Normal  No response 
R24 CD  Normal  Inactive (-8%)  Inactive (-11%) No response 
R27 CD  Normal  Normal   Normal  Strong 
R28 CD  Normal  Normal   Normal  Mild 
R34 CD  Normal  Normal   Normal  Strong 
R35 CD  Inactive (-2%) Normal   Normal  No response 
R37 CD  Normal  Normal   Normal  Strong 
R38 CD  Inactive (-6%) Normal   Normal  No response 
R39 CD  Normal  Normal   Normal  Strong 
C1 Healthy  Normal  Normal   Normal  Mild 
C2 Healthy  Inactive (-2%) Normal   Inactive (-14%) No response 
C3 Healthy  Normal  Incative (-13%)  Normal  No response 
C4 Healthy  Normal  Incative (-7%)  Normal  Mild 
C5 Healthy  Normal  Incative (-10%)  Normal  No response 
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Code Diagnosisa PHAb   Candida albicans c  PWMd   MAP PPDe 
C6 Healthy  Normal  Normal   Normal  No response 
C7 Healthy  Normal  Normal   Normal  No response 
C8 Healthy  Normal  Normal   Normal  No response 
C9 Healthy  Normal  Normal   Normal  No response 
C10 Healthy  Normal  Normal   Normal  No response 
C11 Healthy  Normal  Normal   Normal  No response 
R62    UC  Normal  Normal   Normal  Mild 
a-CD: Crohn’s disease, UC: Ulcerative colitis 
b-PHA: Phytohemagglutinin to assess the overall function of lymphocyte responsiveness 
c-Candida albicans:  Cell extract used to assess the ability of antigen presenting cells to recall antigens 
d-PWM: Pokeweed mitogen to assess B cell responsiveness dependent on T-cell activation 
e-MAP PPD: Purified protein derivative from MAP to assess previous subject’s exposure to the bacterium 
Negative values indicate a decrease in subject’s cell proliferation compared to those from a standard healthy control 
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Table 6: Differentially Expressed Genes Common for both IBD Disorders 
______________________________________________________________________________ 
GenBank    Description        Expression 
______________________________________________________________________________ 
W79396  Zinc finger protein 211   Downregulated 
AI262976  Zinc finger protein 211   Downregulated 
W93370  NKG2-E type II integral membrane protein  Downregulated 
AA463248  CD160 antigen precursor   Downregulated 
AA775616  Secreted phosphoprotein 1   Downregulated 
AA682637  Carbohydrate sulfotransferase 2  Downregulated 
AI371874  Toll-like receptor 4 precursor   Upregulated 
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Table 7: Genes with Differences in the Expression Levels in each subtype of IBD Disorder 
______________________________________________________________________________ 
GenBank    Description   Expression in Expression in    
CD patients UC patients 
_____________________________________________________________________________________________ 
AA083407 Tripartite motif-containing 22   No change Downregulated 
AA476221 Unnamed protein product    Downregulated No change 
AA495985 Small inducible cytokine A18 precursor (CCL18) Downregulated Upregulated 
AI123732 EBV-induced G protein-coupled receptor 2 (EBI2) Downregulated No change 
AA281497 Interferon-gamma receptor alpha 1   Downregulated No change 
R47893 Small inducible cytokine A3 precursor (CCL3)      Downregulated Upregulated 
AA454646 Lymphotoxin-beta receptor   No change Upregulated 
AI298976 Lymphotactin precursor (XCL1)   Downregulated No change 
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Figure 1: Specificity of IS900-derived FITC-labeled DNA Probe. 
The specificity of the DNA probe was evaluated against culture smears from E. coli (A), 
Staphylococcus aurous (B), Mycobacterium. smegmatis (C), Mycobacterium avium subspecies 
avium (D) and MAP (E).  The presence of MAP was detected as a yellow color indicating the 
colocalization of the green FITC-labeled IS900 probe specific for MAP DNA hybridized with 
corresponding genomic MAP DNA present in the bacterial samples using CSLM.  Slides 
containing non-MAP bacterial culture stained with the propidium iodide (red color) indicating 
negative colocalization with the fluorescent IS900 probe. 
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Figure 2: Detection of MAP in spiked tissue by in-situ hybridization. 
The optimized in-situ hybridization technique was evaluated following the analysis of slides with 
normal tissue sections from a colon cancer patient (A) and slides with same tissue spiked with 
MAP culture (B) as visualized by CSLM.  The presence of MAP was detected as a yellow color 
indicating the colocalization of the green FITC-labeled IS900 probe with MAP DNA if present. 
The red staining observed corresponds to tissue stained with the propidium iodide. 
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Figure 3: In-situ identification of MAP DNA in CD tissue samples. 
CLSM images illustrate the presence or absence of MAP in tissue from three CD patients (A, B 
and C).  I corresponds to inflamed tissue and N corresponds to non-inflamed tissue.  The 
presence of MAP was detected as a yellow color indicating the colocalization of the green FITC-
labeled IS900 probe with MAP DNA if present using CSLM. The red staining observed 
corresponds to tissue stained with the propidium iodide.   
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Figure 4: In-situ identification of MAP DNA in non-IBD tissue samples. 
CLSM Images illustrate the absence of MAP DNA in tissue from all six non-IBD patients (A-F). 
MAP DNA, if present, will be visualized as a yellow color indicating the colocalization of the 
green FITC-labeled IS900 probe with MAP genome using CSLM. The red staining observed 
corresponds to tissue stained with the propidium iodide. 
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Figure 5: PCR Detection of MAP DNA in Surgical Tissue Samples. 
PCR product from the second round of the nested PCR was analyzed on 2% agarose gel. An  
amplified 298 bp fragment indicates positive sample for MAP DNA. CD: represent tissue 
samples from CD patients whereas non-IBD represents tissue from colon cancer patients.. NC: 
negative control, PC: positive control, MK: molecular weight marker. Lanes with odd numbers 
represent DNA from Inflamed tissue and even numbers represent those from non-inflamed 
tissue. 
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Figure 6: Nested PCR detection of IS900 DNA Unique to Mycobacterium avium subsp 
paratuberculosis (MAP) in Surgical Tissue. 
Forty three DNA extracts isolated from homogenized tissue specimens from 17 CD and 2 UC 
patients were analyzed by nested PCR. Detection of MAP DNA is indicated by the amplification 
of a 298 bp fragment. Gel A lanes 2, 4, 7, 9, 11, 13, 16, 18, 20, 22, 24 and gel B lanes 4, 7, 10, 13 
represent DNA from non-inflamed tissue from 15 CD patients. Gel A lanes 1, 3, 6, 8, 10, 12, 15, 
17, 19, 21, 23, 25 and gel B lanes 1, 3, 6, 9, 11 represent DNA from inflamed tissue from 17 CD 
patients. DNA from lymph nodes tissue from 7 CD patients is shown in gel A lanes 5, 14, 26 and 
gel B lanes 2, 5, 8, 12. DNA from non-inflamed tissue (lane B16), two inflamed tissue (lanes 
B17 and B14) and one lymph node tissue (lane B15) from two ulcerative colitis patients is also 
shown.  
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Figure 7: Confocal Scanning Laser Microscopy (CSLM) Evaluation of the Phagocytosis of 
FITC-labeled viable and dead bacterial cells by PMN from Healthy subjects. 
Following two h exposure of PMN to 107 CFU of FITC-labeled viable and dead Escherichia coli 
(A and B), FITC-labeled viable and dead Mycobacterium tuberculosis (C and D), and FITC-
labeled viable and dead MAP (E and F), the amount of phagocytosed bacteria was detected by 
green fluorescence.  Using the Zeiss image analysis software, a treshold was applied to eliminate 
pixels with no fluorescence (black) and residual noise from the detector.  The only fluorescence 
detected was the one coming from the inside of the phagocytic cells that is directly proportional 
to the amount of bacterial cells phagocytosed.  Viable and dead bacterial cells were localized 
scattered throughout the cytoplasm inside healthy PMN indicating the disintegration of these 
bacteria inside the macrophages. 
 
.   
67 
A                     B 
 
         C         D 
 
         E          F  
 
68 
  
 
 
 
Figure 8: Confocal Scanning Laser Microscopy (CSLM) Evaluation of the Phagocytosis of 
FITC-labeled viable and dead bacterial cells by PMN from UC subjects. 
Following two h exposure of PMN to 107 CFU of FITC-labeled viable and dead Escherichia coli 
(A and B), FITC-labeled viable and dead Mycobacterium tuberculosis (C and D), and FITC-
labeled viable and dead MAP (E and F), the amount of phagocytosed bacteria was detected by 
green fluorescence.  Using the Zeiss image analysis software, a treshold was applied to eliminate 
pixels with no fluorescence (black) and residual noise from the detector.  The only fluorescence 
detected was the one coming from the inside of the phagocytic cells that is directly proportional 
to the amount of bacterial cells phagocytosed. Viable and dead bacterial cells were localized 
scattered throughout the cytoplasm inside healthy PMN indicating the disintegration of these 
bacteria inside the macrophages. 
. 
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Figure 9: Confocal Scanning Laser Microscopy (CSLM) Evaluation of the Phagocytosis of 
FITC-labeled viable and dead bacterial cells by PMN from CD subjects. 
Following two h exposure of PMN to 107 CFU of FITC-labeled viable and dead Escherichia coli 
(A and B), FITC-labeled, dead Mycobacterium tuberculosis (D), and FITC-labeled viable and 
dead MAP (E and F), the amount of phagocytosed bacteria was detected by green fluorescence.  
Using the Zeiss image analysis software, a treshold was applied to eliminate pixels with no 
fluorescence (black) and residual noise from the detector.  The only fluorescence detected was 
the one coming from the inside of the phagocytic cells that is directly proportional to the amount 
of bacterial cells phagocytosed.  Viable MAP (E) was concentrated in phagosomes closer to the 
cytoplasmic membrane compared to the dead MAP and other bacterial cells seen scattered 
throughout the cytoplasm.  Viable MAP behaved in a way similarly to viable M. tuberculosis 
where a visible phagocytic vacuole containing bacteria is formed from the membrane (C).   
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Figure 10: Confocal Scanning Laser Microscopy (CSLM) of culture PMN from CD 
subjects infected with viable bacteria.  
Following two h exposure of PMN to 107 CFU of FITC-labeled viable Escherichia coli (A), 
FITC-labeled viable Mycobacterium tuberculosis (B), and FITC-labeled viable MAP (C).  The 
amount of phagocytosed bacteria was detected by green fluorescence.  Using the Zeiss image 
analysis software, a treshold was applied to eliminate pixels with no fluorescence (black) and 
residual noise from the detector.  The only fluorescence detected was the one coming from the 
inside of the phagocytic cells that is directly proportional to the amount of bacterial cells 
phagocytosed.  Viable MAP (C) was concentrated in phagosomes closer to the cytoplasmic 
membrane as well as viable TB (B).   
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Figure 11: Biological themes predicted by MeV with EASE microarray analysis 
software. 
We found that 17% (5630 genes) of the total number of genes was differentially 
expressed in both IBD disorders compared to the reference pooled sample.  These genes 
were distributed mainly within four biological themes classified as cellular processes 
(38%), physiological processes (26%), intracellular genes (18%), and genes involved in 
metabolism (18%). 
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Figure 12: Overall variation in the immune response gene expression patterns in human 
white blood cells. 
Of the 5630 genes differentially expressed in the experimental samples, 238 genes belonged 
to genes involved in the immune response.   Eight clusters are shown and the differentially 
expressed genes are boxed either in red boxes (genes that were unique for each IBD disorder) 
or blue boxes (common genes present in both IBD disorders).  The expression levels of the 
IFNGR1 gene is also indicated by a plus sign next to the red box.  Each element is red, green, 
black, or gray.  Black elements have a log ratio (Cy5/Cy3) of 0, while green elements have a 
log ratio of less than 0 and red elements have a log ratio greater than 0.  The further the ratio 
from 0, the brighter the element is.  Gray elements have invalid values and are not used in 
any analysis. 
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